Xeris Pharmaceuticals announced the launch of Gvoke HypoPen™ (glucagon) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and older.
Gvoke HypoPen is a ready-to-use, room-temperature stable liquid glucagon supplied as a prefilled autoinjector in 2 strengths: 0.5mg/0.1mL and 1mg/0.2mL. The product is administered subcutaneously into the lower abdomen, outer thigh, or outer upper arm. For patients weighing <45kg, the recommended dose is 0.5mg, while in those weighing ≥45kg, the recommended dose is 1mg.
Findings from a simulated-use human factors usability study showed that 88% of participants (n=14) were able to successfully administer a rescue injection using the Gvoke HypoPen compared with 31% of those (n=5) using other marketed glucagon emergency kits (P <.05). Mean total rescue time of use was also found to be faster with Gvoke HypoPen vs the other kits (47.9s vs 109.0s; P <.05). Additionally, in a summative human factors validation study involving 75 volunteers, 98.7% were able to successfully administer Gvoke HypoPen following training.
As severe hypoglycemia requires the help of others to recover, patients should be instructed to inform those around them about the appropriate use of Gvoke. Each Gvoke HypoPen comes in an individually packaged, sealed foil pouch and contains a single dose of glucagon; it cannot be reused.
A copay savings card and patient assistance program are also available for eligible patients.
For more information visit gvokeglucagon.com.
This article originally appeared on MPR